Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,506.00
(
0.28%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
91.36
(
0.00%
)
Bitcoin
74,042.42
(
0.39%
)
News Focus
News Focus
Post# of 2265
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

StocktraderDK

Send PM Follow Ignore
Followers 312
Posts 10714
Boards Moderated 16
Alias Born 02/24/2010

StocktraderDK

Re: Giovanni post# 1900

Wednesday, 12/01/2021 5:19:32 PM

Wednesday, December 01, 2021 5:19:32 PM

Post# of 2265
$HEPA
Just so everyone knows that AKRO is starting a 2b Trial for NASH with Fast Track Designation, but has a greatly inferior drug, yet is trading at $20+ with PT in $60+.

So to be comparable, although CRV431 is a much more superior drug WITH MULTIPLE OTHER INDICATIONS, HEPA’s stock should be trading at $10+ with PT of $30+ just to be equally valued…when CRV431 is vastly more valuable!!!

Posted on ST


................ Click HERE To Visit ................

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent HEPA News
More HEPA News